🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

9 recruiting trials

for BCLC Stage B Hepatocellular Carcinoma

Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy NCT07436845n/a1 site📍 Guangzhou Nanfang Hospital, Southern Medical University mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria NCT06607107Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: mFOLFOX7 combined with Camrelizumab and apatinib Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma NCT07154082Phase 21 site📍 Wuhan Wei Zhang · Tests: TACE (transarterial chemoembolization) combined with targeted/immunotherapy Liver Cancer and Immunotherapy in the Liquid Biopsy Era NCT05810402NA1 site📍 Montpellier University Hospital, Montpellier · Tests: Liquid Biopsy Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999694Phase 21 site📍 Taoyuan City Chang Gung Memorial Hospital · Tests: Proton radiotherapy, Tremelimumab, Durvalumab Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC NCT06999707Phase 21 site📍 Taoyuan City Chang Gung Memorial Hospital · Tests: Photon radiotherapy, Tremelimumab, Durvalumab TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria NCT07268131NA1 site📍 Shanghai Fudan University · Tests: TACE+QL1706 HAIC in Combination with PD-1 Inhibitors and Lenvatinib for Intermediate and Advanced HCC After the Failure of Systemic Therapy Recommended by BCLC NCT06632093n/a1 site📍 Shenyang First Hospital of China Medical University · Tests: hepatic artery infusion chemotherapy, Lenvatinib + PD-1 monoclonal antibody Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma NCT06741020Phase 1, Phase 22 sites📍 Hangzhou📍 Hangzhou Zhejiang Cancer Hospital · Tests: Adebrelimab, Oxaliplatin, Fluorouracil,Leucovorin
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy